PORTSMOUTH, N.H., Nov. 14, 2012 /PRNewswire/ -- Novocure™, a commercial stage private oncology company, announced today that preclinical and clinical data from studies evaluating NovoTTF™ Therapy will be presented at the 17th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) in Washington, D.C.
The data presented sheds light on the subcellular mechanisms underlying the anti-cancer effect of NovoTTF Therapy and helps define which recurrent GBM patients respond best to this novel treatment modality.
"We made significant progress in 2012 conducting and supporting research that has the potential to improve the lives of cancer patients around the world," said Eilon Kirson, M.D., Ph.D., Novocure's Chief Science Officer and Head of Research and Development. "We are pleased to present additional clinical data at SNO from the EF-11 pivotal trial, as well as to announce two presentations of pre-clinical data further examining the mechanism of action and efficacy of NovoTTF Therapy."Detailed information about the NovoTTF Therapy presentations are listed below: Date & Time: November 16, 2012, 7pm – 9pm Title: Analysis of the response profile to NovoTTF-100A treatment in patients with recurrent GBM: Time to effect, response duration and transient progressions in the EF-11 phase III trial Poster: NO-47 Presenter: Eric T. Wong, Beth Israel Deaconess Medical Center, Boston, MA Date & Time: November 16, 2012, 7pm – 9pm Title: Efficacy of Tumor Treating Fields (TTFields) and/or radiotherapy (RT) in non-small cell lung cancer (NSCLC) cells Poster: ET-30 Presenter: Katarzyna Zielinska-Chomej, Karolinska Institutet, Stockholm, Sweden Date & Time: November 17, 2012, 5:15pm – 7:15pm Title: Mitosis Interference of Cancer Cells by NovoTTF-100A Causes Decreased Cellular Viability Poster: CB-13 Presenter: Sze Xian Lee, Beth Israel Deaconess Medical Center, Boston, MA In addition to the data presentations, Novocure will be sponsoring a symposium titled "A New Cancer Treatment Modality: Going Beyond Pharmacology with Tumor Treating Fields (TTFields)" presented by Eric T. Wong, M.D. (Beth Israel Deaconess Medical Center) and Manmeet Ahluwalia, M.D., (Cleveland Clinic) on November 17 th from 12pm to 1pm. The symposium will provide clinical perspectives for incorporating the NovoTTF™-100A System into the treatment paradigm for recurrent glioblastoma multiforme (GBM). About GlioblastomaGlioblastoma is the most aggressive and most common form of primary brain tumor in the U.S. The disease affects approximately 10,000 Americans each year. Historically, based on literature, the median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment. The disease is widely recognized as one of the deadliest forms of cancer.